Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia

Pediatr Transplant. 2016 Feb;20(1):158-61. doi: 10.1111/petr.12630. Epub 2015 Nov 14.

Abstract

POI is a relevant late complication after HSCT and occurring more frequently after MAC than after RIC regimens. Reports on the frequency of POI after RIC in a large pediatric and adolescent population are lacking. In this study, we describe a girl affected by CML diagnosed at the age of 15 yr and treated with oncarbide and interferon followed by imatinib and dasatinib. She had two pregnancies shortly after RIC performed according to the CML-SCT I-BFM protocol including TT, FLU, and MEL. Hypergonadotropic hypogonadism occurred four months after HSCT; menstruations resumed regularly six months after HSCT. Eight and 20 months after HSCT, the patient became pregnant and then delivered, respectively, two babies at term by cesarean section. Both newborns had no neonatal complications. Donor chimerism at time of two pregnancies and five yr after transplantation demonstrated complete donor engraftment. These findings suggest that I-BFM CML-SCT protocol could be a promising treatment option for adolescents or young adults with CML eligible for HSCT.

Keywords: chronic myeloid leukemia; premature ovarian insufficiency; reduced intensity conditioning regimen.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / administration & dosage
  • Dasatinib / administration & dosage
  • Disease-Free Survival
  • Drug Administration Schedule*
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Hydroxyurea / administration & dosage
  • Imatinib Mesylate / administration & dosage
  • Interferons / administration & dosage
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Pregnancy
  • Primary Ovarian Insufficiency / prevention & control
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods*
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents
  • Imatinib Mesylate
  • Interferons
  • Dasatinib
  • Hydroxyurea